1. Home
  2. THO vs CINGW Comparison

THO vs CINGW Comparison

Compare THO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THO
  • CINGW
  • Stock Information
  • Founded
  • THO 1980
  • CINGW N/A
  • Country
  • THO United States
  • CINGW United States
  • Employees
  • THO N/A
  • CINGW 13
  • Industry
  • THO Homebuilding
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • THO Industrials
  • CINGW Health Care
  • Exchange
  • THO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • THO N/A
  • CINGW N/A
  • IPO Year
  • THO N/A
  • CINGW 2021
  • Fundamental
  • Price
  • THO $71.03
  • CINGW $0.05
  • Analyst Decision
  • THO Hold
  • CINGW
  • Analyst Count
  • THO 8
  • CINGW 0
  • Target Price
  • THO $93.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • THO 959.5K
  • CINGW N/A
  • Earning Date
  • THO 03-05-2025
  • CINGW N/A
  • Dividend Yield
  • THO 2.82%
  • CINGW N/A
  • EPS Growth
  • THO N/A
  • CINGW N/A
  • EPS
  • THO 3.79
  • CINGW N/A
  • Revenue
  • THO $9,496,171,000.00
  • CINGW N/A
  • Revenue This Year
  • THO N/A
  • CINGW N/A
  • Revenue Next Year
  • THO $7.36
  • CINGW N/A
  • P/E Ratio
  • THO $18.73
  • CINGW N/A
  • Revenue Growth
  • THO N/A
  • CINGW N/A
  • 52 Week Low
  • THO $70.95
  • CINGW N/A
  • 52 Week High
  • THO $118.85
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • THO 29.46
  • CINGW N/A
  • Support Level
  • THO $74.95
  • CINGW N/A
  • Resistance Level
  • THO $79.70
  • CINGW N/A
  • Average True Range (ATR)
  • THO 2.62
  • CINGW 0.00
  • MACD
  • THO 0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • THO 0.95
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: